Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene-related peptide dilation of dural meningeal vessels. Br J Pharmacol. 2002;137:62–68.
American Migraine Foundation,The timeline of a migraine attack. Available from: https://americanmigrainefoundation.org/understanding-migraine/timeline-migraine-attack/ (accessed 03 Feb 2018).Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain. 2011;12:115–125.
Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain. 2011;12:115–125.
Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013;33:408–415.
Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46:57–63.
Ayata C, Lauritzen M. Spreading depression, Spreading depolarizations, and the cerebral vasculature. Physiol Rev. 2015;95:953–993.
Bera S, Khandelwal S, Sood M, Goyal V. A comparative study of psychiatric comorbidity, quality of life and disability in patients with migraine and tension type headache. Neurol India. 2014;62:516–520.
Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology. 2006;67:246–251.
Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7–15.
Bigal ME, Krymchantowski AV, Ho T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq Neuropsiquiatr. 2009;67(2-B):559–569.
Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361–378.
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS).Cephalalgia. 2011;31:301–315.
Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700–714.
Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55:21–34.
Burgos-Vega C, Moy J, Dussor G. Meningeal afferent signaling and the pathophysiology of migraine. Prog Mol Biol Transl Sci. 2015;131:537–564.
Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619–6629.
Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–1470.
Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013;260:1960–1969.
Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain. 2009;5:43.
Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191–1196.
Charles A, Hansen JM. Migraine aura: new ideas about cause, classification, and clinical significance. Curr Opin Neurol. 2015;28:255–260.
Clark SY, Gangula PR. Role of Calcitonin Gene-related Peptide in Gastric Motility Function: Animal and Human Studies. J Gastrointest Dig Syst. 2015;5:2–4.
Cottrell CK, Drew JB, Waller SE, Holroyd KA, Brose JA, O'Donnell FJ. Perceptions and needs of patients with migraine: a focus group study. J Fam Pract. 2002;51:142–147.
de Tommaso M, Sciruicchio V. Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives. Curr Rheumatol Rev. 2016;12:113–126.
Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18(1):96–105.
Demarquay G, Mauguière F. Central nervous system underpinnings of sensory hypersensitivity in migraine: insights from neuroimaging and electrophysiological studies. Headache. 2016;56:1418–1438.
Duman T, Dede ÖH, Uluduz D, Seydaoğlu G, Okuyucu E, Melek İ. Sleep changes during prophylactic treatment of migraine. Ann Indian Acad Neurol. 2015;18:298–302.
Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46:S3–S8.
Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012;136:319–333.
Edvinsson L, Goadsby PJ. Neuropeptides in headache Eur J Neurol. 1998;5:329–341.
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169:683–696.
Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14:65–80.
Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11:1045–1057.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–187.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346:257-270.
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci. 2001;98:4687–4692.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. Also available from https://www.ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf (accessed 06 February 2018).
Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–582.
Karthik N, Kulkarni GB, Taly AB, Rao S, Sinha S. Sleep disturbances in 'migraine without aura'--a questionnaire based study. J Neurol Sci. 2012;321:73–76.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92.
Keezer MR, Bauer PR, Ferrari MD, Sander JW. The comorbid relationship between migraine and epilepsy: a systematic review and meta-analysis. Eur J Neurol. 2015;22:1038–1047.
Kelman L. The postdrome of the acute migraine attack. Cephalalgia. 2006;26:214–220.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54–61.
Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703–711.
Lipton RB and Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.H eadache. 2015;55(Suppl 2):103–122.
Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML. Family impact of migraine: development of the impact of migraine on partners and adolescent children (IMPAC) scale. Headache. 2017;57:570–585.
Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885–894.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349.
Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8(3):e020498.
Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache. 2009;49:1206–1213.
Manzoni GC, Camarda C, Torelli P. Chronification of migraine: what clinical strategies to combat it? Neurol Sci. 2013;34:S57–S60.
Messlinger K. Migraine: where and how does the pain originate? Exp Brain Res. 2009;196:179–193.
Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993;43:S16–S20.
Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016;87:741–749.
Morgan I, Eguia F, Gelaye B, Peterlin BL, Tadesse MG, Lemma S, et al. Sleep disturbances and quality of life in Sub-Saharan African migraineurs. J Headache Pain. 2015;16:18–25.
Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49:498–508.
Naujoks C, M Olson, D Simsek, F de Reydet de Vulpillieres, P Vo, KR Kendall, et al. How do migraines impact patient day-to-day life? An exploratory analysis of patient reported data from the Patientslikeme community. Value Health. 2016;19:A438–A439.
Ng-Mak DS, Fitzgerald KA, Norquist JM, Banderas BF, Nelsen LM, Evans CJ, et al. Key concepts of migraine postdrome: a qualitative study to develop a post-migraine questionnaire. Headache. 2011;51:105–117.
Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013;154:S44–S53.
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B; CDBE2010 study group et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–162.
Parkman HP. Migraine and gastroparesis from a gastroenterologist's perspective. Headache. 2013;53(Suppl 1):4–10.
Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365–391.
Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4:386–398.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W,et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233–246.
Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36. Doi:10.1017/S1462399411002067.
Raggi A, Leonardi M. Burden and cost of neurological diseases: a European North-South comparison. Acta Neurol Scand. 2015;132:16–22.
Renton T, Egbuniwe O. Pain. Part 2a: Trigeminal Anatomy Related to Pain. Dent Update. 2015;42:238-240, 242–244.
Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099–1142.
Russell MB. Genetics of tension-type headache. J Headache Pain. 2007;8:71–76.
Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–552.
Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and hemorrhagic stroke: a meta-analysis. Stroke. 2013;44:3032–3038.
Sadeghniiat K, Rajabzadeh A, Ghajarzadeh M, Ghafarpour M. Sleep quality and depression among patients with migraine. Acta Med Iran. 2013;51:784–788.
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.
Sengul Y, Sengul HS, Bakim B, Yucekaya SK, Yucel S, Akgun M. Sleep disturbances and excessive daytime sleepiness in migraine: A comparison between comorbidities and disability Sleep Biol Rhythms. 2015;13:76–84.
Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356:223–231.
Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123:612–624.
Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15:31.
Stokes M, ecker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058–1077.
Stovner LJ, Andrée C; Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008;9:139–146.
Stuginski-Barbosa J, Dach F, Bigal M, Speciali JG. Chronic pain and depression in the quality of life of women with migraine--a controlled study. Headache. 2012;52:400–408.
Tolner EA, Houben T, Terwindt GM, de Vries B, Ferrari MD, van den Maagdenberg AM. From migraine genes to mechanisms. Pain. 2015;156:S64–S74.
Vos T, GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
Walker HK. Cranial Nerve V: The Trigeminal Nerve. Chapter 61; Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990.
Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170:1293–1307.
Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595–608.
Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315.
Discover acute and preventive migraine treatment options following the AAN and AHS guidelines that include NSAIDs, triptans, ergotamine derivatives, opioids, beta-blockers, calcium channel blockers and tricyclic antidepressants. Future treatments detail CGRP antagonists.
National and international guidelines on all aspects of migraine management including the European Headache Federation (EHF), the European Federation of Neurological Sciences (EFNS) and the International Headache Society (IHS).
Review the terms used in the Migraine Knowledge Centre, along with their definitions including cortical spreading depression, Headache-Attributed Lost Time index (HALT), Hemiplegic migraine and vagus nerve stimulation.